Report #2824291

Received Feb 3, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: PA
Recovered: Unknown
Vaccinated: May 1, 2024
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	—

Symptoms (2)

Inappropriate schedule of product administrationNo adverse event

Symptom narrative

Received First Dose May-2024 and Second Dose in Nov-2024; Initial report received on 27-Dec-2024. A pharmacist reported that a 28-year-old female (race, ethnicity not reported) received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and received the second dose six months later. No medical history or concomitant medications were reported. In May-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLIAV-B (lot #, expiration date, NDC #, site and route not reported). In Nov-2024, approximately six months after receiving HEPLISAV-B, the patient received the second dose of HEPLISAV-B. No adverse reactions were reported. The reporter declined to provided further information. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.